HUE064157T2 - Ciklusos amid származékok alkalmazási eljárásai skizofrénia és tüneteinek kezelésére - Google Patents
Ciklusos amid származékok alkalmazási eljárásai skizofrénia és tüneteinek kezeléséreInfo
- Publication number
- HUE064157T2 HUE064157T2 HUE16181339A HUE16181339A HUE064157T2 HU E064157 T2 HUE064157 T2 HU E064157T2 HU E16181339 A HUE16181339 A HU E16181339A HU E16181339 A HUE16181339 A HU E16181339A HU E064157 T2 HUE064157 T2 HU E064157T2
- Authority
- HU
- Hungary
- Prior art keywords
- symptoms
- methods
- amide derivatives
- cyclic amide
- treat schizophrenia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0003—Two-dimensional division
- H04L5/0005—Time-frequency
- H04L5/0007—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT
- H04L5/001—Time-frequency the frequencies being orthogonal, e.g. OFDM(A) or DMT the frequencies being arranged in component carriers
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/0001—Arrangements for dividing the transmission path
- H04L5/0014—Three-dimensional division
- H04L5/0016—Time-frequency-code
- H04L5/0019—Time-frequency-code in which one code is applied, as a temporal sequence, to all frequencies
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0048—Allocation of pilot signals, i.e. of signals known to the receiver
- H04L5/005—Allocation of pilot signals, i.e. of signals known to the receiver of common pilots, i.e. pilots destined for multiple users or terminals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L5/00—Arrangements affording multiple use of the transmission path
- H04L5/003—Arrangements for allocating sub-channels of the transmission path
- H04L5/0053—Allocation of signalling, i.e. of overhead other than pilot signals
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W4/00—Services specially adapted for wireless communication networks; Facilities therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Signal Processing (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36607510P | 2010-07-20 | 2010-07-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE064157T2 true HUE064157T2 (hu) | 2024-02-28 |
Family
ID=45497166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16181339A HUE064157T2 (hu) | 2010-07-20 | 2011-07-20 | Ciklusos amid származékok alkalmazási eljárásai skizofrénia és tüneteinek kezelésére |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20180155318A1 (enExample) |
| EP (4) | EP3335731B1 (enExample) |
| JP (2) | JP6053678B2 (enExample) |
| KR (1) | KR101867633B1 (enExample) |
| CN (1) | CN103220910B (enExample) |
| BR (1) | BR112013001303A2 (enExample) |
| CA (2) | CA2806017C (enExample) |
| DK (2) | DK2595484T3 (enExample) |
| ES (2) | ES2963362T3 (enExample) |
| FI (1) | FI3135286T3 (enExample) |
| HR (1) | HRP20231446T1 (enExample) |
| HU (1) | HUE064157T2 (enExample) |
| LT (1) | LT3135286T (enExample) |
| NO (1) | NO2595484T3 (enExample) |
| PL (2) | PL3135286T3 (enExample) |
| PT (2) | PT3135286T (enExample) |
| RS (1) | RS64819B1 (enExample) |
| RU (1) | RU2576611C2 (enExample) |
| SI (1) | SI3135286T1 (enExample) |
| SM (1) | SMT202300413T1 (enExample) |
| TW (1) | TWI583679B (enExample) |
| WO (1) | WO2012012542A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL301320B2 (en) * | 2014-12-02 | 2024-11-01 | Minerva Neurosciences Inc | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia |
| CN113694065A (zh) * | 2016-05-25 | 2021-11-26 | 田边三菱制药株式会社 | 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 |
| JP2020525436A (ja) | 2017-06-21 | 2020-08-27 | ミネルバ・ニューロサイエンシズ・インコーポレイテッド | 胃耐性制御放出経口剤形 |
| US20200230127A1 (en) | 2017-10-10 | 2020-07-23 | Neurocrine Biosciences, Inc. | Methods for the Administration of Certain VMAT2 Inhibitors |
| EP3840835A1 (en) * | 2018-08-21 | 2021-06-30 | Minerva Neurosciences, Inc. | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection |
| GB202416895D0 (en) * | 2024-11-18 | 2025-01-01 | Phytoquest Ltd | Treatment of sleep disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE102482T1 (de) * | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| NZ235841A (en) * | 1989-10-27 | 1993-03-26 | Du Pont | (n-phthalimidoalkyl) piperidine derivatives and pharmaceutical compositions |
| EP0497843A4 (en) * | 1989-10-27 | 1992-09-23 | The Du Pont Merck Pharmaceutical Company | (n-phthalimidoalkyl) piperidines |
| NZ521576A (en) * | 2000-02-29 | 2005-06-24 | Mitsubishi Pharma Corp | Novel cyclic amide derivatives |
| US6335371B1 (en) * | 2000-11-28 | 2002-01-01 | Orion Corporation | Method for inducing cognition enhancement |
| JP5281395B2 (ja) * | 2005-06-06 | 2013-09-04 | メルク シャープ エンド ドーム リミテッド | 統合失調症の治療用のglyt1阻害剤としてのシクロヘキサンスルホニル誘導体 |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
-
2011
- 2011-07-20 WO PCT/US2011/044697 patent/WO2012012542A1/en not_active Ceased
- 2011-07-20 FI FIEP16181339.9T patent/FI3135286T3/fi active
- 2011-07-20 BR BR112013001303A patent/BR112013001303A2/pt not_active Application Discontinuation
- 2011-07-20 HU HUE16181339A patent/HUE064157T2/hu unknown
- 2011-07-20 KR KR1020137004217A patent/KR101867633B1/ko active Active
- 2011-07-20 SM SM20230413T patent/SMT202300413T1/it unknown
- 2011-07-20 PT PT161813399T patent/PT3135286T/pt unknown
- 2011-07-20 EP EP17196800.1A patent/EP3335731B1/en active Active
- 2011-07-20 CA CA2806017A patent/CA2806017C/en active Active
- 2011-07-20 DK DK11810349.8T patent/DK2595484T3/en active
- 2011-07-20 JP JP2013520840A patent/JP6053678B2/ja active Active
- 2011-07-20 SI SI201132096T patent/SI3135286T1/sl unknown
- 2011-07-20 ES ES16181339T patent/ES2963362T3/es active Active
- 2011-07-20 HR HRP20231446TT patent/HRP20231446T1/hr unknown
- 2011-07-20 PT PT118103498T patent/PT2595484T/pt unknown
- 2011-07-20 RS RS20231061A patent/RS64819B1/sr unknown
- 2011-07-20 PL PL16181339.9T patent/PL3135286T3/pl unknown
- 2011-07-20 PL PL11810349T patent/PL2595484T3/pl unknown
- 2011-07-20 EP EP11810349.8A patent/EP2595484B1/en active Active
- 2011-07-20 LT LTEP16181339.9T patent/LT3135286T/lt unknown
- 2011-07-20 NO NO11810349A patent/NO2595484T3/no unknown
- 2011-07-20 RU RU2013107382/15A patent/RU2576611C2/ru active
- 2011-07-20 EP EP16181339.9A patent/EP3135286B1/en active Active
- 2011-07-20 CA CA3117855A patent/CA3117855C/en active Active
- 2011-07-20 EP EP24197877.4A patent/EP4494704A3/en active Pending
- 2011-07-20 CN CN201180045067.1A patent/CN103220910B/zh active Active
- 2011-07-20 DK DK16181339.9T patent/DK3135286T3/da active
- 2011-07-20 TW TW100125661A patent/TWI583679B/zh active
- 2011-07-20 ES ES11810349.8T patent/ES2656313T3/es active Active
-
2016
- 2016-08-23 JP JP2016163049A patent/JP6200561B2/ja active Active
-
2017
- 2017-07-21 US US15/656,062 patent/US20180155318A1/en not_active Abandoned
-
2022
- 2022-05-16 US US17/745,024 patent/US20220274951A1/en not_active Abandoned
-
2024
- 2024-08-30 US US18/821,656 patent/US20250179044A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10202009963PA (en) | Melanin modification compositions and methods of use | |
| EP2539005A4 (en) | ORAL PIECE AND METHODS OF USING THE SAME | |
| ZA201308859B (en) | Quinazolines as therapeutic compounds and related methods of use | |
| IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
| IL227440A0 (en) | Spherical support device and methods of use | |
| EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
| IL221476A0 (en) | Methods and compositions to treat hemorrhagic conditions of the brain | |
| PT2683731T (pt) | Derivados de triterpenóides c4-monometil e os métodos de utilização dos mesmos | |
| HRP20171352T1 (hr) | Wnt-antagonisti i postupci liječenja | |
| EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
| ZA201401653B (en) | Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use | |
| IL236830A0 (en) | Diazahomoredene derivatives and methods of using them | |
| ZA201405263B (en) | Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof | |
| GB201302653D0 (en) | Pharmaceutical compositions and methods of treatment | |
| EP2709999A4 (en) | CHINAZOLIN-7-ETHER COMPOUNDS AND ITS APPLICATION | |
| PL3400958T3 (pl) | Kompozycje i metody leczenia celiakii | |
| PT2906221T (pt) | Derivados de amida e ureia de aminoalquilpiperazinas e sua utilização | |
| HUE046572T2 (hu) | TFPI inhibitorok és alkalmazási eljárások | |
| PL2767282T3 (pl) | Zastosowanie glutarylohistaminy w leczeniu infekcji dróg oddechowych | |
| IL256026B (en) | Treatment methods | |
| PL3135286T3 (pl) | Sposoby zastosowania pochodnych amidów cyklicznych do leczenia schizofrenii i jej objawów | |
| ZA201405265B (en) | Derivatives of aza adamantane and uses thereof | |
| EP2672968A4 (en) | ECONAZOL COMPOSITION AND TREATMENT PROCEDURE THEREWITH |